Loading clinical trials...
Loading clinical trials...
Diagnosing invasive pulmonary aspergillosis (IPA) remains a challenge in patients (pts) with hematological malignancies. The clinical significance of testing bronchoalveolar lavage (BAL) samples both with polymerase chain reaction (PCR) and Aspergillus galactomannan (GM) ELISA is unclear, and the BAL cutoff for GM has not been clearly defined yet. Using a validated nested PCR assay and a GM ELISA, we prospectively examine BAL samples from hematological patients at high risk of PA.
Age
5 - 80 years
Sex
ALL
Healthy Volunteers
No
Innsbruck University Hospital
Innsbruck, Austria
Cologne University Hospital
Cologne, Germany
Erlangen University Hospital
Erlangen, Germany
General Hospital Frankfurt (Oder)
Frankfurt (Oder), Germany
Freiburg University Hospital
Freiburg im Breisgau, Germany
Halle University Hospital
Halle, Germany
Herne University Hospital
Herne, Germany
Mannheim University Hospital
Mannheim, Germany
Würzburg University Hospital
Würzburg, Germany
Start Date
April 1, 2007
Primary Completion Date
February 1, 2011
Completion Date
February 1, 2011
Last Updated
April 20, 2020
87
ACTUAL participants
Lead Sponsor
Heidelberg University
NCT03717623
NCT06382922
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT04486885